Cerevel Therapeutics Holdings, (CERE) Financials
CERE Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 1.2 billion | 569.6 million |
2023-09-30 | 822.0 million | 549.0 million |
2023-06-30 | 894.4 million | 543.9 million |
2023-03-31 | 930.3 million | 498.6 million |
CERE Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -98.3 million | 25.2 million |
2023-09-30 | -73.1 million | 17.1 million |
2023-06-30 | -79.4 million | 14.5 million |
2023-03-31 | -95.3 million | 12.6 million |
CERE Net Income
No data available :(
CERE Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 991.0 million | - | 31.2 million |
2023-09-30 | 676.9 million | - | 28.7 million |
2023-06-30 | 736.4 million | - | 29.5 million |
2023-03-31 | 827.0 million | 336.0 million | 30.4 million |
CERE Shares Outstanding
CERE Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 902000 | 97.1 million | 42.4 million | 1.5 million |
2023-09-30 | 513000 | 85.3 million | 26.1 million | - |
2023-06-30 | 2.1 million | 74.1 million | 22.8 million | - |
2023-03-31 | 336000 | 78.2 million | 21.4 million | - |
CERE Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | - | 1.5 million |
2023-09-30 | - | 1.4 million |
2023-06-30 | - | 1.4 million |
2023-03-31 | - | 1.3 million |
CERE
Price: $42.55
52 week price:
Earnings Per Share: -2.67 USD
P/E Ratio: -17.17
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 300700
Market Capitalization: 7.6 billion